Several ongoing trials demonstrate that CPI-613 (devimistat) is a potential treatment for pancreatic cancer, clear cell sarcoma, and biliary tract cancer.
Cell and gene therapies have made incredible strides over the past decade. The 2024 FDA approvals of the first T-cell receptor therapy for the treatment of metastatic synovial sarcoma and the first tumor-infiltrating lymphocyte therapy for the treatment of unresectable or metastatic melanoma mark a significant turning point for solid tumor treatment.xxx:more
